Zura Bio (ZURA) Projected to Release Quarterly Earnings on Thursday

Zura Bio (NASDAQ:ZURA) is expected to issue its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Zura Bio to announce earnings of ($0.22) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 7:00 AM ET.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Tuesday, October 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.20). On average, analysts expect Zura Bio to post ($0.82) EPS for the current fiscal year and ($0.72) EPS for the next fiscal year.

Zura Bio Stock Down 69.7%

Shares of NASDAQ ZURA opened at $1.24 on Tuesday. The business’s 50 day moving average price is $4.36 and its two-hundred day moving average price is $5.18. The company has a market cap of $118.83 million, a PE ratio of -1.11 and a beta of 0.03. Zura Bio has a twelve month low of $0.93 and a twelve month high of $7.44.

Analyst Ratings Changes

ZURA has been the subject of several research analyst reports. Wedbush lifted their target price on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Guggenheim restated a “buy” rating on shares of Zura Bio in a research note on Friday, October 30th. Weiss Ratings raised Zura Bio from a “sell (d-)” rating to a “sell (d)” rating in a report on Wednesday, October 28th. Finally, Wall Street Zen raised shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zura Bio has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Zura Bio Company Profile

Zura Bio, Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company’s research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage.

Zura Bio’s lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor.